### 1 Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of

## 2 methadone providers under counterfactual scenarios

- 3
- 4 Eric Tatara<sup>1,2\*</sup>, Qinyun Lin<sup>3</sup>, Jonathan Ozik<sup>1,2</sup>, Marynia Kolak<sup>3</sup>, Nicholson Collier<sup>1,2</sup>, Dylan Halpern<sup>3</sup>, Luc
- 5 Anselin<sup>3</sup>, Harel Dahari<sup>4</sup>, Basmattee Boodram<sup>5</sup>, and John Schneider<sup>6</sup>
- 6
- <sup>7</sup><sup>1</sup>Consortium for Advanced Science and Engineering, University of Chicago, Chicago, IL, USA.
- 8 <sup>2</sup>Decision and Infrastructure Sciences, Argonne National Laboratory, Lemont, IL, USA.
- 9 <sup>3</sup>Center for Spatial Data Science, University of Chicago, Chicago, IL, USA.
- 10 <sup>4</sup>The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of
- 11 Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
- <sup>5</sup>Division of Community Health Sciences, School of Public Health, University of Illinois at Chicago,
- 13 Chicago, IL, USA.
- <sup>6</sup>University of Chicago Medicine, Department of Infectious Disease, Chicago, IL, USA.
- 15
- 16 **\*Corresponding author:**
- 17 Email: <u>tatara@anl.gov</u> (ET)
- 18
- 19 Declarations of competing interest: None of the authors have any financial interest or conflict of
- 20 interest related to this research.
- 21
- 22 Key words: MOUD; opioid use disorder; persons who inject drugs; agent-based modeling; methadone

### 23 ABSTRACT

24 Access to treatment and medication for opioid use disorder (MOUD) is essential in reducing opioid use 25 and associated behavioral risks, such as syringe sharing among persons who inject drugs (PWID). Syringe 26 sharing among PWID carries high risk of transmission of serious infections such as hepatitis C and HIV. 27 MOUD resources, such as methadone provider clinics, however, are often unavailable to PWID due to 28 barriers like long travel distance to the nearest methadone provider and the required frequency of clinic 29 visits. The goal of this study is to examine the uncertainty in the effects of travel distance in initiating and 30 continuing methadone treatment and how these interact with different spatial distributions of 31 methadone providers to impact co-injection (syringe sharing) risks. A baseline scenario of spatial access 32 was established using the existing locations of methadone providers in a geographical area of 33 metropolitan Chicago, Illinois, USA. Next, different counterfactual scenarios redistributed the locations of 34 methadone providers in this geographic area according to the densities of both the general adult 35 population and according to the PWID population per zip code. We define different reasonable 36 methadone access assumptions as the combinations of short, medium, and long travel distance 37 preferences combined with three urban/suburban travel distance preference. Our modeling results show 38 that when there is a low travel distance preference for accessing methadone providers, distributing 39 providers near areas that have the greatest need (defined by density of PWID) is best at reducing syringe 40 sharing behaviors. However, this strategy also decreases access across suburban locales, posing even 41 greater difficulty in regions with fewer transit options and providers. As such, without an adequate 42 number of providers to give equitable coverage across the region, spatial distribution cannot be optimized 43 to provide equitable access to all PWID. Our study has important implications for increasing interest in 44 methadone as a resurgent treatment for MOUD in the United States and for guiding policy toward 45 improving access to MOUD among PWID.

### 46 INTRODUCTION

47 Access to treatment and medication for opioid use disorder (MOUD) is essential in reducing behavioral 48 risks for HIV and HCV infection and overdose associated with injection drug use [1-3]. In addition to 49 individual competing priorities (e.g., unstable housing, childcare), barriers to access to MOUDs among 50 people who inject drugs (PWID) may include structural factors (e.g., drug use-related stigma [4], long 51 travel distances, or policy barriers [5]). Historical, socioeconomic, racial, and other structural factors 52 influence both availability and perception of MOUDs [5–7]. Furthermore, there is a high degree of 53 variability in individual MOUD pharmacology, delivery, and patient preference. As a golden standard to 54 address MOUD access inequities, MOUDs should be available in all communities to facilitate treatment 55 individualization and treatment support retention. As such, understanding access to MOUDs, health 56 services, and other harm reduction services (e.g., syringe service programs) is critical to defining risk 57 environment landscapes that affect fatal and nonfatal overdoses and HIV and HCV infections related to 58 injection drug use.

59

60 Effective prevention and treatment strategies exist for opioid use disorder (OUD) but are highly 61 underutilized in the United States. Indeed, only a small fraction (11%) who need MOUD received it in 2020 62 [8]. Methadone, a synthetic opioid agonist that eliminates withdrawal symptoms and relieves drug 63 cravings by acting on opioid receptors in the brain, is the medication with the longest history of use for 64 OUD treatment, having been used since 1947. A large number of studies support methadone's 65 effectiveness at reducing opioid use [9], but have also shown methadone access disparities along racial, 66 ethnic socio-demographics, and geographic location. While expedient access to methadone maintenance 67 treatment is critical to preventing overdose death [10], at this time its provisioning is restricted to federally 68 licensed opioid treatment program (OTP) locations, which tend to reflect carceral approaches to 69 treatment such as strict patient surveillance, limited flexibility in medication schedules, and high

frequency of travel to OTP locations [5,11]. While access to other MOUDs such as buprenorphine has increased across the US due in part to fewer administrative restrictions, people with OUD deserve options for treatment and many patients prefer methadone even with the geographic access barriers: a factor that motivates the current analysis [12]. This has led to a resurgence in efforts to remove administrative restrictions on clinics and providers to provide methadone to treat OUD among people who use drugs [5].

75

76 The goal of this study is to examine the uncertainty in the effects of travel distance in initiating and 77 continuing methadone treatment for OUD and how these uncertainties interact with different spatial 78 distributions of methadone providers to impact co-injection (syringe sharing) risks among PWID. 79 Behavioral risk mitigation (i.e., reduction in syringe sharing) is often a function of the complex interplay 80 of historical, sociological, and structural factors, resulting in nuanced patterns that reflect underlying 81 social and spatial inequities. Research on access to primary health services often cite a preference for a 82 less than 30-minute travel time for individuals seeking care [13,14], though a recent survey on driving 83 times to OTPs showed that almost 18% of the US population would have driving times in excess of 30 84 minutes to the nearest OTP, and almost 37% of individuals in rural counties experiencing OTP drive times 85 over an hour [15]. Currently, more than a third of continental U.S. zip codes are more than an hour away 86 from treatment, and access to methadone providers remains worse than other MOUD types (ex. 87 buprenorphine and naltrexone) [16]. Providing transportation services has been shown to improve 88 treatment retention for methadone maintenance programs and outpatient drug-free programs [17] and 89 transportation costs have been shown to be a significant factor in travel to OTPs [15]. Minoritized 90 racial/ethnic status has been associated with admission delays for outpatient methadone treatment [6] 91 and reduced likelihood of being offered pharmacologic support for recovery [18] - though once engaged 92 in treatment, have similar retention rates to the majority of clients [19]. At the same time, minoritized 93 groups may prefer accessing treatment services within primary care settings versus specialty mental

health clinics [20]. While geographic access to treatment is crucial, access is a multidimensional concept
that can be deconstructed into the components of availability, accommodation, affordability, and
acceptability [21]. For persons with OUD, access is especially complex because of the interplay of MOUD
resource scarcity and drug use stigma, as patients experiencing stigma from MOUD providers are less
likely to return [22].

99

100 Measuring spatial access to public resources like OTPs must consider the frequency of resource utilization 101 and the mode of transit to the resource [23]. Travel hardships, including extended distances, longer travel, 102 and interstate commute, have been considered as the most common accessibility barriers for people who 103 seek care from distant providers, especially for persons in rural areas where public transportation is 104 limited [15,24–27]. Most existing studies focus on actual distance to MOUD locations and very few have 105 studied what is the *ideal* distance (or travel time) preferences to ensure accessibility. The effect of travel 106 hardships on accessibility is most critical for methadone considering the need for daily dosing. Increased 107 distance to treatment can impede daily attendance as shown in a recent study of patients receiving MOUD 108 treatment that found patients residing 10 miles from the treatment facility were more likely to miss doses 109 compared to those who lived within 5 miles [28]. Conventional interventional trials test whether 110 modification of spatial factors is needed, but often difficult and costly to implement.

111

There is a need for more rapid approaches to assessing and translating spatial epidemiologic findings to practical real-world interventions that benefit proven, yet underutilized interventions such as methadone treatment for MOUD. We examine the impact of methadone provider distribution on syringe sharing among PWID from Chicago, IL, USA and the surrounding suburbs using a validated agent-based model (ABM) (Hepatitis C Elimination in Persons Who Inject Drugs or HepCEP) [2]. Our modeling approach accounts for uncertainties in how individuals perceive access to methadone providers and how that

perception affects their decisions to initiate and adhere to MOUD treatment. As such, we employ a robust decision making perspective [29] to capture the effects of different methadone provider distribution approaches across these uncertainties.

121

### 122 METHODS

### 123 HepCEP Model

124 The current study extends our previous work on simulating the PWID population in Chicago and the 125 surrounding suburbs, Illinois, USA, including drug use and syringe sharing behaviors, and associated 126 infection dynamics [2,30]. The demographic, behavioral, and social characteristics of the PWID population 127 is generated using data from five empirical datasets on metropolitan Chicago (urban and suburban) area 128 PWID that is previously described [30]. In brief, this includes data from a large syringe service program 129 (SSP) enrollees (n=6,000, 2006-13) [31], the IDU data collection cycles of the National HIV Behavioral 130 Surveillance (NHBS) survey from 2009 (n=545) [32] and 2012 (n=209) [33], and a social network and 131 geography study of young (ages 18-30) PWID (n=164) [34]. Data analyses from these sources is used to 132 generate attributes for each of the estimated 32,000 PWID in the synthetic population for metropolitan 133 Chicago [35] in the model and includes: age, age of initiation into injection drug use, gender, 134 race/ethnicity, zip code of residence, HCV infection status, drug sharing network degree, parameters for 135 daily injection and syringe sharing rates, and harm reduction/syringe service program (SSP) enrollment 136 [30]. PWID agents may leave the population due to age-dependent death or drug use cessation and are 137 replaced with new PWID sampled from the input data set to maintain a nearly constant population size 138 of 32,000 for the entire course of the simulation.

139

Syringe sharing among PWID is modeled in HepCEP via dynamic syringe sharing networks. Network
 formation is determined by the probability of two PWID encountering each other in their neighborhood

142 of residence and within the outdoor drug market areas in Chicago that attracts both urban and non-urban 143 PWID for drug purchasing and utilization of SSPs that are also located in the same areas [36]. The methods 144 used to calculate network encounter rates, establishment processes, and removal of networks have been 145 described previously [30]. Each modeled individual has an estimated number of in-network PWID partners 146 who give syringes to the individual and out-network PWID partners who receive syringes from the 147 individual. The network edge direction determines the flow of contaminated syringes between 148 individuals, and thus the direction of disease transmission. The network evolves over time, and during the 149 course of the simulation some connections (ties) may be lost, while new ties form, resulting in an 150 approximately constant network size.

151

152 MOUD treatment enrollment is modeled in two steps. First, there is an unbiased awareness of MOUD 153 resources by PWID, capturing the knowledge that agents possess about the existence of a methadone 154 provider. The annual target awareness rate, defined as the total annual awareness as a fraction of the 155 total population, is a model parameter with a constant value of 90%. Thus, over the course of a year, 90% 156 of the PWID population will be made aware of MOUD treatment and, subsequently decide whether to 157 engage in MOUD treatment. The total PWID target MOUD treatment awareness for a single day is 158 determined by the daily mean treatment awareness, which is the total PWID population multiplied by the 159 annual treatment awareness parameter / 365. The daily awareness target is sampled from a Poisson 160 distribution using the daily mean treatment awareness.

161

PWID that receive MOUD treatment experience a reduction in the number of daily drug injections, which
is determined by multiplying the PWID's baseline pre-MOUD daily drug injection frequency by a reduction
multiplier sampled from a uniform distribution from 0 to 0.25 [37]. Thus, the mean reduction in daily

injection frequency is 87% when on MOUD treatment compared to when not on MOUD. Reduction indaily injection frequency reduces the number of syringe sharing episodes with other infected individuals.

167

## 168 Reasonable Geographic Access Assumptions

169 Our approach to model the initiation and continuation of MOUD treatment incorporates multiple aspects 170 of access to care: 1) the travel distance to the nearest methadone provider from the PWID place of 171 residence, 2) the frequency of clinic visits, and 3) racial/ethnic inequalities to treatment as represented 172 by the geospatial heterogeneity of the PWID population demographics. PWID first decide to enroll in 173 MOUD treatment and then subsequently decide to continue treatment every 7 days, a duration chosen 174 to reflect the average frequency of clinic visits for the treatment over time. Average overall treatment 175 duration for methadone is obtained from literature to be 150 days [38] and different urban and non-urban 176 travel distance preferences to the nearest methadone provider are used by PWID to determine if they will 177 or will not enroll in MOUD treatment (Table 1). The probability that a PWID will enroll in MOUD treatment 178 is greater when the treatment travel distance is below the travel distance preference.

179 Table 1. Travel distance to methadone provider preferences used for reasonable geographic access

180 assumptions. The table represents six different possible combinations of low, medium, and high travel

181 distance preferences considering three urban/suburban distance preference combinations for each low,

182 medium, high distance preference pair with a maximum distance limit, and three corresponding low,

183 medium, and high distance preference pairs with no maximum distance limit.

	Travel Distance to Methadone Provider (miles)							
	With Maxim	um Distance Limit	No Maximum Distance L					
	Urban	Suburb/Rural	Urban	Suburb/Rural				
Travel Distance Preference								
Low	1 (max: 15)	5 (max: 60)	1	5				
Medium	2 (max: 15)	10 (max: 60)	2	10				
High	5 (max: 15)	20 (max: 60)	5	20				

We define six different possible combinations of low, medium, and high travel distance preferences considering three urban/suburban distance preference combinations for each low, medium, high travel distance preference pair with a maximum travel distance preference, and three corresponding low, medium, and high travel distance preferences pairs with no maximum distance preference (Table 1). In the cases with maximum preferences, the individuals will not be able to access treatment if the provider is farther away than the maximum preferred travel distance.

190

191 To approximate reasonable geographic access, the travel distance in miles from zip code centroid to the 192 nearest methadone provider is calculated using the sf package in R (version 4.0.2) [39]. Methadone 193 treatment requires frequency of visits comparable to that of people's grocery shopping (daily or weekly) 194 [40,41], and travel distances of 1 mile (urban) and 10 miles (suburban/rural) areas is reasonable for 195 community members, respectively, to their grocery stores. Because of the scarcity of methadone 196 providers, we extend the urban reasonable travel distance preference to 2 miles. Published findings 197 indicate that access to mental health treatment within 10 miles is associated with greater attendance in 198 persons with OUD [42]. Accordingly, the travel distance preference of "reasonable geographic access" to 199 the methadone provider is set at 2 miles in urban areas, which approximates a 30-minute walking 200 distance, and for suburban and rural areas, the travel distance preference is set at 10 miles (Table 1).

201

As there is limited information on how geographic access affects individuals' decision to seek treatment, an additional layer of uncertainty is introduced via penalties on individuals' probability of getting treatment when the geographic travel distance exceeds the reasonable access distance preference but is below the maximum distance limit. If the travel distance exceeds the preference, the per-decision probability of treatment is lower (by a factor  $\theta$ ) than if the PWID is closer to the provider. Since  $\theta$  is not easily estimated, values are chosen ranging from 60% to 90% for this study, which represents broad per-

decision penalties for accessing locations beyond distance preferences. The base probabilities are calculated by using the distribution of the PWID agent population under the actual spatial distribution of methadone providers (see below) and under different preference scenarios to match the overall methadone treatment duration values. Each penalty level is combined with each of the six travel distance preference combinations in Table 1, resulting in 18 separate parameter combinations, or reasonable access assumptions.

214

### 215 Spatial Distribution of Methadone Providers

## 216 MOUD Provider Data

217 This study includes data on methadone maintenance MOUD providers in Chicago and the surrounding 218 suburbs, which we define as the 298 zip codes from Cook County (i.e., the most populous county in Illinois 219 and includes Chicago) and the five collar counties that border Cook, which are also the next five most 220 populous counties in the state. We include providers beyond these boundaries for the state of Illinois to 221 provide context in interpretation, though only perform simulations and evaluate scenarios within these 222 boundaries. A total of 81 Illinois providers are identified by specifying "methadone maintenance" from 223 the Substance Abuse and Mental Health Service Administration (SAMHSA) Behavioral Health Treatment 224 Service Locator (derived from the 2019 National Survey of Substance Abuse Treatment Service) [43].

225

### 226 Counterfactual Methadone Provider Spatial Distributions

To study how the spatial distribution of methadone providers affects syringe sharing behaviors among PWID, three counterfactual distributions are generated to spatially redistribute methadone provider locations. That is, the geographic locations of methadone providers are changed and re-evaluated for accessibility to those providers. In all scenarios, the total number of all methadone providers in Illinois is assumed to be constant (n = 81).

Spatially random: MOUD treatment locations are randomly distributed within the study area (298 zip codes in Cook and five collar counties) and other areas (1085 zip codes) in Illinois. The total number of modelled methadone providers in Illinois remains unchanged; only the location of these resources changes. This distribution provides a useful null hypothesis of spatial randomness that can be benchmarked against actual geographic distribution of resources, as well as alternate counterfactual distributions.

238

239 **Need-based 1**: Methadone provider locations are assigned proportionally to the adult population (age 18-240 39) within each zip code which results in more methadone providers assigned to zip codes with larger 241 adult populations. The Hamilton (largest remainder) method [44] is used to calculate the number of 242 methadone providers assigned to each zip code and to ensure that each area was assigned an integer 243 number of methadone providers. Specifically, methadone providers are first allocated to each zip code 244 proportional to the local at-risk population. The result for each zip code consists of an integer part plus a 245 fractional remainder, or in some cases, only a fractional remainder. Each zip code is first allocated an 246 integer number of providers. This leaves some providers unallocated. The zip codes are then ranked based 247 on the fractional remainders: one additional methadone provider is added to the zip code areas ranking 248 the highest until all providers are allocated.

249

Need-based 2: In this distribution, methadone providers are assigned proportionally to the total PWID population [30] for each zip code. The difference between *Need-based 1* and *Need-based 2* is how the need for methadone within each zip code area is estimated. Need-based 2 is potentially better reflects local geographic needs as the PWID population likely represents a closer approximation for the need for methadone providers than an area's entire adult population.

255

### 256 Outcome: Syringe sharing

257 The reduction in annual syringe sharing events among PWID who are adherent to methadone treatment 258 relative to a baseline scenario without methadone availability is investigated as the main outcome of 259 interest of the simulation studies. Syringe sharing reduction is calculated for each of the 18 reasonable 260 access assumptions in each of the three counterfactual methadone provider distributions, along with the 261 actual provider distribution. A baseline simulation is first conducted to determine the number of annual 262 syringe sharing events in each zip code when PWID have no awareness of methadone providers, and do 263 not enroll in MOUD treatment. The baseline is not sensitive to provider distribution or travel distance 264 preference since no MOUD treatment occurs.

265

266 For each combination of reasonable access assumption and provider distribution, the syringe sharing 267 reduction metric is defined as the difference in the number of annual syringe sharing events in each zip 268 code when PWID are aware of methadone providers, relative to the baseline. The HepCEP model is run 269 for a 20-year period starting in 2010 through simulated year 2030. The total number of syringe sharing 270 events in each zip code is tabulated only for year 2030, resulting in the metrics for annual syringe sharing 271 reduction. The simulation time frame is based on the need to initialize the model using population data 272 calibrated to year 2010, and to allow the model population and network dynamics to stabilize, as has been 273 done in prior studies [22,24].

274

A total of 1,440 simulations were conducted using high-performance computing workflows implemented with the EMEWS framework [45]. The 1,440 runs include 20 stochastic replicates for each of the 72 parameter sets, where each parameter set corresponds to the four provider spatial distributions for each of the 18 reasonable access assumptions. We report the mean number of syringe sharing episodes across

the 20 stochastic replicates. The simulation experiments were executed on the Bebop cluster run by the
Laboratory Computing Resource Center at Argonne National Laboratory.

281

282 Annual syringe sharing reduction relative to baseline (no MOUD) is aggregated across all zip codes to 283 produce a single scalar metric for each of the 72 parameter sets. We define a decision regret score to 284 represent the difference in syringe sharing reduction for each of the four spatial provider distributions, 285 relative to the spatial distribution with the largest reduction in syringe sharing, for each combination of 286 reasonable access assumptions. A decision regret score of zero represents the best outcome in terms of 287 reducing syringe across each of the four spatial provider distributions, for a specific combination of 288 reasonable access assumptions. Conversely, a high regret score means that the scenario had a significantly 289 larger number of syringe sharing episodes relative to the best scenario with the fewest number of syringe 290 sharing episodes.

291

The 75th-percentile of the regret score distribution for each of the four provider spatial distribution scenarios is used to evaluate the robustness for each spatial strategies, i.e., adequate performance over a wide range of possible ground truths and decision-making uncertainties.

295

## 296 **RESULTS**

### 297 Spatial access to methadone providers under different reasonable geographic access assumptions


Figure 1 provides a geographic illustration of whether each zip code minimum travel distance to a methadone provider is within the travel distance preference of reasonable geographic access (Table1), underlying different assumptions of what is the ideal distance to ensure accessibility. The first, second, and third row in Figure 1 corresponds to the low, middle, and high travel distance preferences, respectively in Table 1. For each travel distance preference (each row in Figure 1), the four figures


303	(columns in Figure 1) show each zip code's accessibility to the nearest methadone provider under the
304	actual spatial distribution of providers and three counterfactual spatial distributions.

305


Comparing the actual provider spatial distribution with the two need-based distributions (Figure 1, column-wise), we identify areas where the need for methadone providers is high while the spatial access to providers is limited. For example, some areas in Chicago have high need but few providers, and accessibility to methadone providers are improved in the two need-based counterfactual distributions.

Comparing across rows in Figure 1, more zip codes have better spatial access to methadone providers as we assume a higher travel distance preference (i.e., people are able and willing to travel longer distances). This preference does not account for transit barriers such as travel time and access to public transit infrastructures, vehicles, as well as the financial cost of transit. Under the low travel distance preference that likely reflects real-world barriers to transit, few areas have reasonable geographical access to methadone providers. Therefore, simply redistributing methadone providers spatially may not provide better access when the number of individual providers is limited.





Medium Preference Assumption: 2 miles urban, 10 miles suburban



High Preference Assumption: 5 miles urban, 20 miles suburban

Spatially Accessible Zip Code Area
 Not Spatially Accessible Zip Code Area
 City of Chicago Boundary
 County Boundary

40 mi 20 0

Coordinate Reference System: EPSG: 3857, WGS 84/Pseudo-Mercator

- 318 319 320 321
- 322

Figure 1. Spatial access to methadone providers for the actual scenario and three counterfactual distribution scenarios, under varying travel distance preference assumptions. Each dot represents the location of a single methadone provider. City of Chicago and collar county borders are indicated. Spatial access to methadone providers is calculated as distance to nearest provider to the center of each zip code area; thus in the low travel distance preference assumption, zip codes areas are not identified as accessible if there is no provider within a mile of its geographic center.

329 330

331 Effects of spatial distribution of methadone providers on annual syringe sharing reduction by zip code 332 Since the total number of methadone providers are fixed in this analysis, redistributing provider locations 333 in the counterfactual distributions relative to the actual distribution leads to some areas having a higher 334 reduction in syringe sharing events than others. The reduction in the number of annual syringe sharing 335 events (relative to baseline) in each zip code for the actual provider distribution (Figure 2, columns 1 and 336 5), under each reasonable access assumption reflect the zip code provider spatial accessibility in Figure 1. 337 The change in syringe sharing reduction by zip code, relative to the actual distribution, highlights the 338 effects of spatially redistributing methadone providers in each of the three counterfactual distributions 339 (Figure 2, columns 2-3 and 6-8). Blue colored zip codes indicate a larger reduction in annual syringe sharing 340 events than the actual distribution, while red colored zip codes indicate a lesser reduction in syringe 341 sharing than the actual distribution.

342

Simulation scenarios across a range of methadone provider location distributions and spanning the spectrum from least optimistic reasonable access assumptions (Figure 2, upper rows, low travel distance preference, maximum travel distance, and a penalty of 0.6.) to the most optimistic access assumptions (Figure 2, lower rows, high travel distance preference, no travel distance maximum, and a penalty of 0.9) demonstrate a high degree of spatial heterogeneity in the expected reduction in syringe sharing events among PWID in Chicago, IL and surrounding suburbs.

**Syringe Sharing Reduction (Actual Distribution)** A higher value (darker color) represents greater nee-

dle sharing reduction by ZIP Code.

# 129.7 605.5 2,112.6 4707

#### **Change in Syringe Sharing Reduction**

The change difference in needle sharing reduction across three scenarios that modify the distribution of resources.

> -2.5k	-1,250	0	+1,250	> +2.5k




Figure 2. Effects of reasonable access to methadone assumptions on syringe sharing events by zip code for each scenario in Cook County IL and surrounding counties. Columns 1 and 5 represent the reduction in syringe sharing events for the actual spatial distribution of methadone providers, relative to the baseline scenario without methadone. In the other columns, blue colored zip codes indicate a greater reduction in syringe sharing events relative to the actual scenario, while red colored zip codes indicate a lesser reduction in syringe sharing events relative to the actual scenario.


356

### 357 **Robustness of spatial methadone provider distributions in reducing annual syringe sharing events**

The spatial variation of syringe sharing reduction across reasonable access assumptions (Figure 2) reflects heterogeneity in the PWID population both in terms of local population density, and in terms of drug use behaviors and co-injection risks reflected in the underling empirical population data used in the model. Since the underlying individual PWID behaviors are difficult to observe in reality, optimizing provider spatial distributions to reduce the number of syringe sharing events may not be an appropriate goal; rather, the robustness of spatial distributions that perform well over a wide range of possible ground truths and decision-making uncertainties are examined.

365

366 Figure 3 provides a visual representation of the regret scores for the annual reduction in syringe sharing 367 events for each of the 18 reasonable access assumptions, grouped by the four spatial distributions of 368 methadone providers (Supporting Information Tables S1, S2). Each point in Figure 3 represents the regret 369 score for each of the reasonable access assumptions, color coded by travel distance preference (Table1). 370 Given the definition of regret scores, lower values represent a more ideal outcome (less regret) for a 371 particular reasonable access assumption, i.e., values of zero indicate that the spatial provider distribution 372 had the largest reduction in syringe sharing events for the indicated reasonable access assumption. Vertical box plots for each spatial provider distribution in Figure 3 provide the median, 25<sup>th</sup> and 75<sup>th</sup> 373 374 percentiles for regret score.



375

376 Figure 3. Regret score of annual reduction in needle sharing by travel distance preference and spatial 377 distribution of methadone providers. Each dot represents the regret score for each of the 18 reasonable 378 access assumptions (three travel distance preferences with and without maximum distance plus three 379 distance penalty values). Vertical box plots for each spatial provider distribution provide the median, 25<sup>th</sup> 380 and 75<sup>th</sup> percentiles. Whisker lines indicate minimum and maximum regret values. The regret score 381 represents the difference in syringe sharing reduction for each of the four spatial provider distributions, 382 relative to the spatial distribution with the largest reduction in syringe sharing, for all combinations of 383 reasonable access assumptions. A decision regret score of zero represents an ideal outcome in that the 384 spatial distribution was best at reducing syringe sharing for a given reasonable access assmption. 385 Conversely, a high regret score means that the scenario had a significantly larger number of syringe 386 sharing episodes relative to the best scenario with the fewest number of syringe sharing episodes.

- 387
- 388

389	Figure 3 therefore helps to provide insight as to how reasonable access assumptions impact individuals'
390	decisions to initiate and continue methadone treatment. The need-based 2 distribution (PWID density)
391	performs better than the need-based 1 (total population density) and actual distributions when spatial
392	access to providers is important (i.e., low travel distance preference and higher barriers to travel,
393	represented as orange dots). The need-based 1 distribution performs better than the need-based 2 and
394	actual distributions under medium and high travel distance preference (e.g. willingness to travel further
395	and lesser barriers to travel, represented as blue and green dots).

396

The actual provider distribution results in a greater reduction in syringe sharing events than the needbased 2 distribution (PWID density) only when assuming a high travel distance preference (green dots), while it performs much worse than both need-based distributions when assuming low travel distance preference (orange dots). Notably, the actual provider distribution does not achieve a zero (best) regret score for any combination of reasonable access assumptions (Figure 3). In all cases, the spatially random distribution generates the worst result (Figure 3).

403

Based on a 75<sup>th</sup> percentile regret metric for each of the four spatial provider distributions, the Need-based
2 spatial distribution (PWID density) represents a more robust distribution of methadone providers with
respect to reducing annual syringe sharing events, across the uncertainties around all reasonable access
assumptions and travel distance preferences (Figure 3, fourth column).

408

## 409 **DISCUSSION**

Our agent-based modeling study of PWID from Chicago and the surrounding Illinois suburbs provides
 valuable insights into the development of future interventions to enhance MOUD treatment uptake by
 PWID. We found that the impact of the spatial distribution of methadone providers on syringe sharing

413 frequency is dependent on assumptions of access. When there is a low travel distance preference for 414 accessing methadone providers, i.e., PWID are faced with significant structural barriers, distributing providers near areas that have the greatest need (defined by density of PWID) is optimal (Figure 3). 415 416 However, this strategy also decreases access across suburban locales, posing even greater difficulty in 417 regions with fewer transit options and providers (Figure 2). As such, without an adequate number of 418 providers to give equitable coverage across the region, spatial redistribution cannot be optimized to 419 provide equitable access to all persons (and potential persons) with OUD. Policies that would expand 420 geographic access to methadone maintenance treatment by making it available at pharmacies and/or 421 federally gualified health centers may better meet the need of this population [15,46,47], and are 422 currently an area of vigorous debate and consideration [5].

423

The PWID population in Chicago and the surrounding suburbs [48] and other urban areas [35] is wellcharacterized. Detailed and current knowledge on PWID demographics can be used to study how access to MOUD treatment providers can be improved over existing resource distributions, along with estimates of future needs due to shifts in PWID demographics and locations.

428

For all reasonable access assumptions and provider location distributions, spatially redistributing methadone providers relative to the actual distribution may effectively decrease access in some areas. There were no scenarios that exhibited zero areas with worse access compared to the actual scenario, highlighting the scarcity of providers in the region as a major challenge. Geospatial visualization of our simulation results (Figures 1 and 2) show that the more remote and less populated areas remained inaccessible, reflecting urban-suburban accessibility challenges. Underserved areas could be supplemented with mobile treatment providers to target these vulnerable populations.

437 Under modeling scenarios with substantial uncertainties as in the current study, particularly related to 438 underlying individual behaviors that are difficult to observe, optimizing spatial provider distributions to 439 reduce syringe sharing among PWID may not be an appropriate goal. Instead, robust [29] methadone 440 provider location distributions that perform well over a wide range of possible ground truths and 441 uncertainties should be sought. Detailed, data-driven, agent-based models combined with the capacity 442 for large-scale computational experimentation, can provide such analyses to support decision making 443 under uncertainties, or when empirical data collection is costly or unethical. Our results show that the 444 Need-based 2 spatial distribution (PWID density) represents the most robust distribution of methadone 445 providers with respect to reducing annual syringe sharing events, across the uncertainties around all 446 reasonable access assumptions and travel distance preferences (Figure 3, fourth column).

447

448 Need-based counterfactuals were more like the actual provider distribution than the spatially random 449 distribution, suggesting that some areas' needs for methadone providers are being met. However, some 450 geographic locales remain in high need of providers, as demonstrated by the need-based scenarios 451 (Figures 1 and 2). McHenry county, in the northeastern part of the study area, is notable for having all or 452 most of its zip codes characterized by no access in all travel distance preference assumptions – despite a 453 large PWID population in need of MOUD treatment options. Many nearby suburban counties likewise 454 have a patchwork of access across travel distance preference assumptions. While some regions of Chicago 455 have access to providers, more access on transit-connected northern and lake coastal sides of the city 456 would better support populations who currently need, or may need, treatment.

457

The low travel distance preference assumption highlights multiple, significant gaps in access across the Chicago area and surrounding suburban counties. While this assumption may seem restrictive, it may also be the most realistic. For example, 1- and 5-miles traveled in urban or suburban areas for a resource

required daily or weekly is considered exceptionally reasonable in food access literature (where grocery stores may also be accessed weekly). This low travel distance preference assumption may also be optimistic because of additional social, economic, and structural barriers faced at opioid treatment programs providing methadone services, like cost and drug use stigma (experienced at the provider and/or neighborhood that it is located within). Our study has important implications for guiding policy toward improving access to MOUD among PWID, particularly in areas where the population is dispersed, e.g., expansive suburban areas in large metropolitan cities like Chicago.

468

## 469 Limitations

470 Our current results report reductions in annual syringe sharing events for all combinations of reasonable 471 access assumption and provider spatial distributions. Downstream health sequelae such as hepatitis C and 472 HIV have been examined in previous work [2,49] in the PWID population; however, the current study did 473 not show significant associated reductions in HCV infection in most zip codes, even as the number of 474 syringe sharing events are reduced compared to baseline (data not shown). The most likely explanation is 475 that since the current study does not implement HCV treatment and other harm reduction services (e.g., 476 sterile syringe and equipment provision), simply reducing the syringe sharing frequency in a highly 477 connected PWID network is not sufficient to eliminate new HCV infection without also reducing the 478 disease incidence.

Second, the reported results include the annual reduction in syringe sharing for only a single simulation year (2030). Time-varying trends in syringe sharing metrics were not investigated. Further, the PWID population is maintained at a constant size of 32,000 individuals for the course of the simulation. Although we model transient changes in PWID demographics as in previous studies [2,30], we believe that the PWID population size may be somewhat close to constant given that people who transition to MOUDs is balanced out by new initiates into injection drug use entering the population.

485

## 486 Acknowledgements

- 487 This work is supported by the National Institute on Drug Abuse (NIH) grant U2CDA050098 (The
- 488 Methodology and Advanced Analytics Resource Center), by the National Institute of General Medical
- 489 Sciences grant R01GM121600, by the National Institute of Allergy and Infectious Diseases (NIH) grant
- 490 R01AI158666, by the National Institute on Drug Abuse (NIH) grant R01DA043484, and by the U.S.
- 491 Department of Energy under contract number DE-AC02-06CH11357, and was completed with resources
- 492 provided by the Laboratory Computing Resource Center at Argonne National Laboratory (Bebop cluster).
- 493 The research presented in this paper is that of the authors and does not necessarily reflect the position
- 494 or policy of the National Institute on Drug Abuse or any other organization.

## 495 **REFERENCES**

- Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4: 435–444. doi:10.1016/S2468-1253(19)30085-8
- Tatara E, Gutfraind A, Collier NT, Echevarria D, Cotler SJ, Major ME, et al. Modeling hepatitis C
   micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan
   Chicago. PLOS ONE. 2022;17: e0264983. doi:10.1371/journal.pone.0264983
- Tatara E, Schneider J, Quasebarth M, Collier N, Pollack H, Boodram B, et al. Application of
   Distributed Agent-based Modeling to Investigate Opioid Use Outcomes in Justice Involved
   Populations. 2021 IEEE International Parallel and Distributed Processing Symposium Workshops
   (IPDPSW). 2021. pp. 989–997. doi:10.1109/IPDPSW52791.2021.00157
- Williams LD, Mackesy-Amiti ME, Latkin C, Boodram B. Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs.
   Drug Alcohol Depend. 2021;221: 108626. doi:10.1016/j.drugalcdep.2021.108626
- 5. Meyerson BE. Opportunities and Challenges: Hepatitis C Testing and Treatment Access Experiences
   Among People in Methadone and Buprenorphine Treatment During COVID-19, Arizona, 2021. 2023.
- 6. Andraka-Christou B. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid
  Use Disorder. Health Aff (Millwood). 2021;40: 920–927. doi:10.1377/hlthaff.2020.02261
- Meyerson BE, Bentele KG, Russell DM, Brady BR, Downer M, Garcia RC, et al. Nothing really
   changed: Arizona patient experience of methadone and buprenorphine access during COVID. PLOS
   ONE.
- 516 8. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health
  517 Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health.
  518 2021. Available: https://www.samhsa.gov/data
- 519 9. Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH. Patterns in admission delays to
  520 outpatient methadone treatment in the United States. J Subst Abuse Treat. 2011;41: 431–439.
  521 doi:10.1016/j.jsat.2011.06.005
- 522 10. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for Opioid Use
  523 Disorder After Nonfatal Opioid Overdose and Association With Mortality. Ann Intern Med.
  524 2018;169: 137–145. doi:10.7326/M17-3107
- 525 11. Joudrey PJ, Edelman EJ, Wang EA. Methadone for Opioid Use Disorder—Decades of Effectiveness
  526 but Still Miles Away in the US. JAMA Psychiatry. 2020;77: 1105.
  527 doi:10.1001/jamapsychiatry.2020.1511
- 528 12. Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone,
  529 buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug Alcohol
  530 Depend. 2016;160: 112–118. doi:10.1016/j.drugalcdep.2015.12.031

- 13. Bosanac EM, Parkinson RC, Hall DS. Geographic Access to Hospital Care: A 30-Minute Travel Time
   Standard: Med Care. 1976;14: 616–624. doi:10.1097/00005650-197607000-00006
- 533 14. Brustrom JE, Hunter DC. Going the distance: how far will women travel to undergo free534 mammography? Mil Med. 2001;166: 347–349.
- 535 15. Kleinman RA. Comparison of Driving Times to Opioid Treatment Programs and Pharmacies in the US.
   536 JAMA Psychiatry. 2020;77: 1163–1171. doi:10.1001/jamapsychiatry.2020.1624
- 537 16. Joudrey PJ, Kolak M, Lin Q, Paykin S, Anguiano V, Wang EA. Assessment of Community-Level
  538 Vulnerability and Access to Medications for Opioid Use Disorder. JAMA Netw Open. 2022;5:
  539 e227028. doi:10.1001/jamanetworkopen.2022.7028
- 540 17. Friedmann PD, Lemon SC, Stein MD. Transportation and retention in outpatient drug abuse
  541 treatment programs. J Subst Abuse Treat. 2001;21: 97–103. doi:10.1016/s0740-5472(01)00185-4
- 542 18. Knudsen HK, Roman PM. Financial Factors and the Implementation of Medications for Treating
  543 Opioid Use Disorders. J Addict Med. 2012;6: 280–286. doi:10.1097/ADM.0b013e318262a97a
- 544 19. Elwy AR, Ranganathan G, Eisen SV. Race-ethnicity and diagnosis as predictors of outpatient service
  545 use among treatment initiators. Psychiatr Serv Wash DC. 2008;59: 1285–1291.
  546 doi:10.1176/ps.2008.59.11.1285
- 547 20. Snowden LR, Pingitore D. Frequency and scope of mental health service delivery to African
  548 Americans in primary care. Ment Health Serv Res. 2002;4: 123–130. doi:10.1023/a:1019709728333
- 549 21. Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer
   550 satisfaction. Med Care. 1981;19: 127–140. doi:10.1097/00005650-198102000-00001
- Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people
  who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198: 80–86.
  doi:10.1016/j.drugalcdep.2019.01.037
- Talen E, Anselin L. Assessing Spatial Equity: An Evaluation of Measures of Accessibility to Public
   Playgrounds. Environ Plan Econ Space. 1998;30: 595–613. doi:10.1068/a300595
- 4. Heil SH, Sigmon SC, Jones HE, Wagner M. Comparison of Characteristics of Opioid-Using Pregnant
  Women in Rural and Urban Settings. Am J Drug Alcohol Abuse. 2008;34: 463–471.
  doi:10.1080/00952990802122358
- 25. Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers
  to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse.
  2020;46: 273–288. doi:10.1080/00952990.2019.1694536
- Solution 26. Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance Traveled and CrossState Commuting to Opioid Treatment Programs in the United States. J Environ Public Health.
  2011;2011: 1–10. doi:10.1155/2011/948789

27. Ridgway JP, Almirol EA, Schmitt J, Schuble T, Schneider JA. Travel Time to Clinic but not
Neighborhood Crime Rate is Associated with Retention in Care Among HIV-Positive Patients. AIDS
Behav. 2018;22: 3003–3008. doi:10.1007/s10461-018-2094-5

28. Amiri S, Lutz R, Socías ME, McDonell MG, Roll JM, Amram O. Increased distance was associated with
lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst
Abuse Treat. 2018;93: 26–30. doi:10.1016/j.jsat.2018.07.006

571 29. Lempert RJ. Robust Decision Making (RDM). In: Marchau VAWJ, Walker WE, Bloemen PJTM, Popper
572 SW, editors. Decision Making under Deep Uncertainty: From Theory to Practice. Cham: Springer
573 International Publishing; 2019. pp. 23–51. doi:10.1007/978-3-030-05252-2\_2

574 30. Gutfraind A, Boodram B, Prachand N, Hailegiorgis A, Dahari H, Major ME. Agent-Based Model
575 Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing
576 Prevalence of Hepatitis C Infections. Kaderali L, editor. PLOS ONE. 2015;10: e0137993.
577 doi:10.1371/journal.pone.0137993

578 31. Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: a longitudinal
 579 study. J Acquir Immune Defic Syndr 1999. 2007;45: 108–114. doi:10.1097/QAI.0b013e318050d260

32. Lansky A, Abdul-Quader AS, Cribbin M, Hall T, Finlayson TJ, Garfein RS, et al. Developing an HIV
Behavioral Surveillance System for Injecting Drug Users: The National HIV Behavioral Surveillance
System. Public Health Rep. 2007;122: 48–55.

33. Mackesy-Amiti ME, Boodram B, Spiller MW, Paz-Bailey G, Prachand N, Broz D, et al. InjectionRelated Risk Behavior and Engagement in Outreach, Intervention and Prevention Services Across 20
US Cities. J Acquir Immune Defic Syndr. 2017;75 Suppl 3: S316–S324.
doi:10.1097/QAI.00000000001406

587 34. Boodram B, Mackesy-Amiti M-E, Latkin C. The role of social networks and geography on risky
588 injection behaviors of young persons who inject drugs. Drug Alcohol Depend. 2015;154: 229–235.
589 doi:10.1016/j.drugalcdep.2015.06.042

590 35. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HLF, Hall HI, et al. Trends in the Population
591 Prevalence of People Who Inject Drugs in US Metropolitan Areas 1992–2007. Khudyakov YE, editor.
592 PLoS ONE. 2013;8: e64789. doi:10.1371/journal.pone.0064789

36. Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H. High-Risk Geographic Mobility Patterns
among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members.
J Urban Health Bull N Y Acad Med. 2018;95: 71–82. doi:10.1007/s11524-017-0185-7

59637. Corsi KF, Lehman WK, Booth RE. The effect of methadone maintenance on positive outcomes for597opiate injection drug users. J Subst Abuse Treat. 2009;37: 120–126. doi:10.1016/j.jsat.2008.11.004

38. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative
 Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3:
 e1920622. doi:10.1001/jamanetworkopen.2019.20622

- 39. Pebesma E. Simple Features for R: Standardized Support for Spatial Vector Data. R J. 2018;10: 439–
  446.
- 603 40. Blanchard T, Matthews T. Retail Concentration, Food Deserts, and Food Disadvantaged
  604 Communities in Rural America. Remaking the North American Food System: Strategies for
  605 Sustainability. University of Nebraska Press; 2009.
- 41. Jiao J, Moudon AV, Ulmer J, Hurvitz PM, Drewnowski A. How to Identify Food Deserts: Measuring
  Physical and Economic Access to Supermarkets in King County, Washington. Am J Public Health.
  2012;102: e32–e39. doi:10.2105/AJPH.2012.300675
- 609 42. Schmitt SK, Phibbs CS, Piette JD. The influence of distance on utilization of outpatient mental health
  610 aftercare following inpatient substance abuse treatment. Addict Behav. 2003;28: 1183–1192.
  611 doi:10.1016/S0306-4603(02)00218-6
- 43. Home SAMHSA Behavioral Health Treatment Services Locator. [cited 2 May 2022]. Available:
   https://findtreatment.samhsa.gov/
- 44. US Census Bureau CHS. Methods of Apportionment History U.S. Census Bureau. [cited 3 Oct
  2023]. Available:
- 616 https://www.census.gov/history/www/reference/apportionment/methods\_of\_apportionment.html
- 617 45. Ozik J, Collier NT, Wozniak JM, Spagnuolo C. From desktop to Large-Scale Model Exploration with
  618 Swift/T. 2016 Winter Simulation Conference (WSC). 2016. pp. 206–220.
  619 doi:10.1109/WSC.2016.7822090
- 46. Iloglu S, Joudrey PJ, Wang EA, Thornhill TA, Gonsalves G. Expanding access to methadone treatment
  in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling
  analysis. Drug Alcohol Depend. 2021;220: 108534. doi:10.1016/j.drugalcdep.2021.108534
- 47. Joudrey PJ, Edelman EJ, Wang EA. Methadone for Opioid Use Disorder-Decades of Effectiveness but
  Still Miles Away in the US. JAMA Psychiatry. 2020;77: 1105–1106.
  doi:10.1001/jamapsychiatry.2020.1511
- 48. Boodram B, Mackesy-Amiti ME, Khanna A, Brickman B, Dahari H, Ozik J. People who inject drugs in
  metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and
  computational modeling toward hepatitis C microelimination. PLOS ONE. 2022;17: e0248850.
  doi:10.1371/journal.pone.0248850
- 49. Tsang MA, Schneider JA, Sypsa V, Schumm P, Nikolopoulos GK, Paraskevis D, et al. Network
  Characteristics of People Who Inject Drugs Within a New HIV Epidemic Following Austerity in
  Athens, Greece. JAIDS J Acquir Immune Defic Syndr. 2015;69: 499.
  doi:10.1097/QAI.000000000665

634

# 636 Supporting Information

637

## 638 Table S1. Overall syringe sharing reduction and regret scores under for each reasonable access

## 639 **assumption under each scenario.**

640

Threshold	Penalty	Max dist		Needle shari	ng reduction	Best (max)	Regret score				
		threshold	Actual	S1	S2	S3	Dest (max)	RS_Actual	RS_S1	RS_S2	RS_S3
1/5	0.6	F	870K	429K	943K	1,013K	1,013K	143K	584K	70K	0
1/5	0.6	т	870K	429K	943K	1,016K	1,016K	146K	587K	73K	0
1/5	0.75	F	895K	486K	972K	1,043K	1,043K	148K	557K	71K	0
1/5	0.75	т	902K	486K	972K	1,034K	1,034K	132K	548K	62K	0
1/5	0.9	F	985K	656K	1,036K	1,097K	1,097K	112K	441K	61K	0
1/5	0.9	т	980K	656K	1,036K	1,087K	1,087K	107K	431K	51K	01
2/10	0.6	F	1,014K	713K	1,108K	1,050K	1,108K	94K	395K	OK	58
2/10	0.6	т	1,007K	713K	1,108K	1,062K	1,108K	101K	395K	OK	46
2/10	0.75	F	1,016K	734K	1,120K	1,063K	1,120K	103K	385K	OK	57
2/10	0.75	т	1,020K	734K	1,120K	1,063K	1,120K	100K	385K	OK	56
2/10	0.9	F	1,050K	823K	1,117K	1,078K	1,117K	66K	294K	OK	39
2/10	0.9	т	1,045K	823K	1,117K	1,076K	1,117K	72K	294K	OK	41
5/20	0.6	F	1,059K	807K	1,073K	1,042K	1,073K	14K	266K	OK	30
5/20	0.6	т	1,061K	807K	1,073K	1,044K	1,073K	11K	266K	OK	29
5/20	0.75	F	1,062K	826K	1,079K	1,052K	1,079K	17K	254K	OK	27
5/20	0.75	т	1,071K	826K	1,079K	1,047K	1,079K	8K	254K	OK	32
5/20	0.9	F	1,065K	896K	1,083K	1,060K	1,083K	18K	187K	OK	23
5/20	0.9	т	1,072K	896K	1,083K	1,053K	1,083K	10K	187K	OK	30
							75th percentile RS	111K	439K	58K	40

641 642

643	Table S1 shows the syringe sharing reduction outcome for each reasonable access assumption under
644	each scenario, along with regret scores. For example, when the ideal geographical travel distance
645	preference is set to be low (i.e., 1 mile for urban and 5 miles for suburban), penalty equals to 0.6, and
646	we do not set a maximum limit, Scenario 3 (Need-based 2) generates the most syringe sharing reduction
647	(1,013K, see first row in Table S1). Accordingly, the regret score for each other scenario is the difference
648	between their syringe sharing reduction result and Scenario 3 (Need-based 2). In this case, Scenario 1
649	(spatially random) generates the largest regret score, meaning we expect the syringe sharing reduction
650	to be the lowest in this case. In the last row of Table S1, we report the 75th percentile of regret scores
651	across each of the18 reasonable access assumptions for each scenario, from which we observe that the
652	two Need-based scenarios (Scenario 2 and Scenario 3) perform the best. Notably, the Actual scenario
653	performs worse than the two Need-based scenarios but better than the Random scenario.
654 655	

# 656 Table S2. Overall syringe sharing reduction relative risk and regret scores for each reasonable access

## 657 **assumption under each scenario**.

658

	Ον	erall Needle	Sharing Re	duction Rel	ative Risk	(Enrollment	90%/Enro	llment 0%, zip c	ode weight	ed by Enrol	lment 0%)	
exp		Penalty	Threshold	Actual	S1	S2	S3	Best (min)	RS_Actual	RS_S1	RS_S2	RS_S3
1		0.6	1/5	0.567	0.786	0.530	0.495	0.495	0.071	0.291	0.035	0.000
2		0.6	2/10	0.495	0.645	0.448	0.477	0.448	0.047	0.197	0.000	0.029
3		0.6	5/20	0.472	0.598	0.466	0.481	0.466	0.007	0.132	0.000	0.015
4	No Max	0.75	1/5	0.554	0.758	0.516	0.480	0.480	0.074	0.278	0.035	0.000
5	Distance	0.75	2/10	0.494	0.634	0.442	0.470	0.442	0.052	0.192	0.000	0.028
6	Threshold	0.75	5/20	0.471	0.589	0.462	0.476	0.462	0.009	0.126	0.000	0.014
7		0.9	1/5	0.509	0.673	0.484	0.453	0.453	0.056	0.220	0.030	0.000
8		0.9	2/10	0.477	0.590	0.444	0.463	0.444	0.033	0.146	0.000	0.019
9		0.9	5/20	0.469	0.554	0.461	0.472	0.461	0.009	0.093	0.000	0.011
10		0.6	1/5	0.567	0.786	0.530	0.494	0.494	0.073	0.293	0.036	0.000
11		0.6	2/10	0.498	0.645	0.448	0.471	0.448	0.050	0.197	0.000	0.023
12	1.1.1.1.1.1.0.0	0.6	5/20	0.471	0.598	0.466	0.480	0.466	0.006	0.132	0.000	0.014
13	Max 15/60	0.75	1/5	0.550	0.758	0.516	0.485	0.485	0.066	0.273	0.031	0.000
14	miles	0.75	2/10	0.492	0.634	0.442	0.470	0.442	0.050	0.192	0.000	0.028
15	Distance Threshold	0.75	5/20	0.466	0.589	0.462	0.478	0.462	0.004	0.126	0.000	0.016
16	rnesholu	0.9	1/5	0.512	0.673	0.484	0.459	0.459	0.053	0.215	0.025	0.000
17		0.9	2/10	0.479	0.590	0.444	0.464	0.444	0.036	0.146	0.000	0.020
18		0.9	5/20	0.466	0.554	0.461	0.475	0.461	0.005	0.093	0.000	0.015
								75th percentile RS	0.055	0.219	0.029	0.020

Note. RS represents regret score.